ReviewMolecules (Basel, Switzerland)2020
Approaches to PET Imaging of Glioblastoma.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Metabolic Imaging as Future Technology and Innovation in Brain-Tumour Surgery: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- PET-based Radiomics Analysis for Predicting Prognosis and Differentiation Treatment-Related Changes in Glioma: A Systematic Review.Journal of biomedical physics & engineering · 2026Article
- Amino Acid Transporters in Glioblastoma: Implications for Diagnosis, Disease Monitoring, Therapeutic Targeting, and Drug Delivery.Molecular diagnosis & therapy · 2025Review
- Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions.Cancer innovation · 2025Review
- Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?Diagnostics (Basel, Switzerland) · 2025Article
- Emerging insights into the immunosuppressive tumor microenvironment and its implications for glioblastoma immunotherapy.Frontiers in immunology · 2025Review
- Assessing the role of FET-PET imaging in glioblastoma recurrence: A retrospective analysis of diagnostic accuracy.Brain & spine · 2025Article
- Targeting drug resistance in glioblastoma (Review).International journal of oncology · 2024Review
- Microbubble-Enhanced Focused Ultrasound for Infiltrating Gliomas.Biomedicines · 2024Review
- Review
- Transmembrane pH gradient imaging in rodent glioma models.NMR in biomedicine · 2024Article
- Biosensor-Enhanced Organ-on-a-Chip Models for Investigating Glioblastoma Tumor Microenvironment Dynamics.Sensors (Basel, Switzerland) · 2024Review
- Dioxinodehydroeckol: A Potential Neuroprotective Marine Compound Identified by In Silico Screening for the Treatment and Management of Multiple Brain Disorders.Molecular biotechnology · 2024Article
- Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.Journal of neuro-oncology · 2024Article
- pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells.Neuro-oncology · 2024Article
- [Theranostics · 2024Article
- A Review of Hypoxia Imaging Using 18F-Fluoromisonidazole Positron Emission Tomography.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Advances in Diagnostic Tools and Therapeutic Approaches for Gliomas: A Comprehensive Review.Sensors (Basel, Switzerland) · 2023Review
- Review
- Fluorinated carbohydrates forChemical Society reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma multiforme (GBM) is the deadliest type of brain tumor, affecting approximately three in 100,000 adults annually. Positron emission tomography (PET) imaging provides an important non-invasive method of measuring biochemically specific targets at GBM lesions. These powerful data can characterize tumors, predict treatment effectiveness, and monitor treatment. This review will discuss the PET imaging agents that have already been evaluated in GBM patients so far, and new imaging targets with promise for future use. Previously used PET imaging agents include the tracers for markers of proliferation ([
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.